뉴스센터 >
보도자료
1월 27, 2023
United States
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
1월 18, 2023
The Netherlands
Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
12월 16, 2022
Belgium
Janssen Withdraws Application in European Union Seeking Approval of IMBRUVICA (ibrutinib) for the Treatment of Patients with Untreated Mantle Cell Lymphoma
12월 12, 2022
United States
Real-World Study Shows Patients Treated with IMBRUVICA (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia

닫기